• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

NIH grants over $500M to cre­ate an­tivi­rals for fu­ture pan­demics

4 years ago
R&D

Covid-19 roundup: WHO val­i­dates an­oth­er shot; Ashish Jha chimes in on the state of vac­cines and ther­a­peu­tics

4 years ago
Pharma
Coronavirus

An­oth­er biotech that went pub­lic in pan­dem­ic boom aims to weath­er the bear mar­ket through R&D cut­backs

4 years ago
People
R&D

Go­ing for broke, Tri­ci­da is slam­ming the brakes on a piv­otal tri­al ear­ly while plan­ning a run at the FDA

4 years ago
R&D

FDA com­mis­sion­er an­nounces new role for Janet Wood­cock, down­shift­ing away from drugs

4 years ago
FDA+

Pfiz­er teams up with dig­i­tal ther­a­peu­tics part­ner for next prod­uct launch, this time in atopic der­mati­tis

4 years ago
Deals
Marketing

Not one, not two, but three — biotech claims it will pur­sue CARs T, M and NK all at once

4 years ago
Financing
Startups

Re­silience inks man­u­fac­tur­ing pact with ARCH-backed cell ther­a­py start­up as it preps for the long haul

4 years ago
Deals
Manufacturing

With mon­key­pox cas­es ris­ing, one Eu­ro­pean coun­try is lock­ing down a small­pox vac­cine con­tract

4 years ago
Pharma
Manufacturing

As Big Phar­ma cir­cles RSV wag­ons, biotech re­ports mid-stage flop for its an­tivi­ral

4 years ago
R&D

PhRMA's court win over HHS could be a boon for phar­ma pa­tient as­sis­tance pro­grams

4 years ago
Pharma
Law

In­fa­mous biotech ex­ec Mar­tin Shkre­li gets out of prison, hits the street

4 years ago
People

J&J opens up con­ver­sa­tions around de­pres­sion in the LGBTQ+ com­mu­ni­ty with new cam­paign

4 years ago
Pharma
Marketing

Amid ris­ing con­cern of re­sis­tance, Pfiz­er lim­its sup­ply of Paxlovid for com­bi­na­tion stud­ies — re­port

4 years ago
Pharma
Coronavirus

De­spite fed­er­al ef­forts to di­ver­si­fy clin­i­cal tri­als, progress re­mains 'stag­nan­t' — re­port

4 years ago
Pharma

Bavar­i­an Nordic se­cures BAR­DA con­tract for small­pox vac­cine

4 years ago
Deals
Pharma

Ab­b­Vie ex­pands use of re­al pa­tients in lat­est Al­ler­gan Aes­thet­ics DTC cam­paign

4 years ago
Pharma
Marketing

House com­mit­tee unan­i­mous­ly ad­vances FDA user fee leg­is­la­tion with ac­cel­er­at­ed ap­proval tweaks

4 years ago
FDA+

New FTC com­mis­sion­er could turn the tide for an in­ves­ti­ga­tion in­to PBMs

4 years ago
Pharma

Fed­er­al judge weighs mo­tion to dis­miss HeLa law­suit against Ther­mo Fish­er

4 years ago
Law

Pfiz­er, Sarep­ta and two oth­ers sug­gest Duchenne drug safe­ty is­sues tied to "class ef­fect"

4 years ago
R&D
Cell/Gene Tx

Af­ter lay­ing off a fourth of its staff, gene ther­a­py start­up Swan­Bio sees fresh fi­nanc­ing as it heads to­wards the ...

4 years ago
Financing
Cell/Gene Tx

Mod­er­na starts up third HIV vac­cine tri­al, part­ner­ing with IAVI to study its shot in Africa

4 years ago
R&D

Flag­ship builds a new start­up out of pieces from 2 of its biotechs. And a Roche vet leaves to do some­thing new

4 years ago
People
Startups
First page Previous page 528529530531532533534 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times